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Abstract
Animal models of multiple myeloma vary in terms of consistency of onset, degree of tumour
burden and degree of myeloma bone disease. Here we describe five pre-clinical models of
myeloma in NOD/SCID-GAMMAmice to specifically study the effects of therapeutic agents
on myeloma bone disease. Groups of 7–8 week old female irradiated NOD/SCID-GAMMA
mice were injected intravenously via the tail vein with either 1x106 JJN3, U266, XG-1 or
OPM-2 human myeloma cell lines or patient-derived myeloma cells. At the first signs of mor-
bidity in each tumour group all animals were sacrificed. Tumour load was measured by
histological analysis, and bone disease was assessed bymicro-CT and standard histomor-
phometric methods. Mice injected with JJN3, U266 or OPM-2 cells showed high tumour bone
marrow infiltration of the long bones with low variability, resulting in osteolytic lesions. In con-
trast, mice injected with XG-1 or patient-derived myeloma cells showed lower tumour bone
marrow infiltration and less bone disease with high variability. Injection of JJN3 cells into
NOD/SCID-GAMMAmice resulted in an aggressive, short-term model of myeloma with mice
exhibiting signs of morbidity 3 weeks later. Treating these mice with zoledronic acid at the
time of tumour cell injection or once tumour was established prevented JJN3-induced bone
disease but did not reduce tumour burden, whereas, carfilzomib treatment given once tumour
was established significantly reduced tumour burden. Injection of U266, XG-1, OPM-2 and
patient-derived myeloma cells resulted in less aggressive longer-termmodels of myeloma
with mice exhibiting signs of morbidity 8 weeks later. Treating U266-induced disease with
zoledronic acid prevented the formation of osteolytic lesions and trabecular bone loss as well
as reducing tumour burden whereas, carfilzomib treatment only reduced tumour burden. In
summary, JJN3, U266 or OPM-2 cells injected into NOD/SCID-GAMMAmice provide robust
models to study anti-myeloma therapies, particularly those targeting myeloma bone disease.
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Introduction
Multiple myeloma (MM) is a cancer of differentiated B-lymphocytes leading to the clonal ex-
pansion of plasma cells in the bone marrow (BM). Despite continually improving treatments,
myeloma is almost always incurable. One of the most debilitating features of MM is the devel-
opment of osteolytic bone disease, which results in increased susceptibility to bone fractures,
bone pain and hypercalcaemia. A number of pre-clinical animal models of MM have been de-
veloped to assess the efficacy of therapeutic agents used in the treatment of myeloma bone dis-
ease (MBD) [1–7]. Most recently the immune-suppressed NOD/SCID-GAMMA (NSG) strain
of mice has been used successfully in human xenograft models of MM. In these studies, a num-
ber of myeloma cell lines [8–12] and patient-derived myeloma cells [10–12] were injected into
NSG mice leading to varying levels of BM infiltration. The effect of anti-tumour agents on the
growth of myeloma cells and the overall survival of animals has also been assessed in various
NSG models [8, 9, 13–15]. However, there is limited information on the development of osteo-
lytic disease in these models [3, 11, 16, 17]. Further investigation is required to identify and
validate the best models in terms of consistency of onset, degree of tumour infiltration and
extent of MBD.
In 2004, Miyakawa et al. [16] were the first group to inject U266 cells (a myeloma cell line)
into NSG mice via the tail vein. This showed U266 infiltration of the BM at the end stages of
disease by fluorescence-activated cell sorting (FACS) using an anti-human CD45 antibody and
by the presence of human IgE (which is produced by the U266 cells) in histological BM sec-
tions. They also demonstrated, by histological analysis, that U266 BM infiltration caused the
development of osteolytic lesions. Similarly Hofgaard et al. [3] showed that BM infiltration of
MOPC315.BM.Luc cells (a mineral oil-induced plasmacytoma) in NSG mice resulted in an in-
crease of tartrate-resistant acid phosphatase (TRAP) positive osteoclasts in histological sec-
tions. However, assessment of bone disease in both of these models was limited to histological
analysis only. More recently, Hurchla et al. [17] performed micro-computed tomography
(micro-CT) analysis to assess bone disease in NSG mice intravenously injected with RPMI-
8266 cells, which resulted in BM infiltration and osteolytic disease. Treating these mice with
oprozomib, a proteasome inhibitor, reduced the tumour growth of myeloma cells in the BM
when assessed by fluorescent imaging and analysis of human IgGλ levels in serum. Further-
more, micro-CT analysis showed that oprozomib prevented tumour-induced trabecular bone
loss and reduced serum levels of the bone turnover marker carboxy terminal telopeptide
(CTX) as well as increasing levels of pro-collagen 1 N-terminal peptide (P1NP).
Taken together, there is limited information on MBD in NSG mice injected with myeloma
cell lines or patient-derived cells. There is therefore a prerogative to identify and validate the
best murine myeloma models in terms of consistency of tumour burden and extent of MBD.
Consistency and reliability between animals is essential for meaningful pre-clinical evaluation
of anti-myeloma therapies, particularly those targeting MBD.
The aim of this report was firstly, to determine the time to onset of disease, the variability in
tumour burden and the extent of bone disease in NSG mice injected with 4 different myeloma
cell lines or patient-derived cells; and secondly, to assess the use of NSG myeloma models for
the evaluation of bone therapeutics. We hypothesised that NSG mice injected with a BM-
derived myeloma cell line (JJN3) would develop severe bone disease at a faster rate than mice
injected with peripheral blood-derived cells (U266, XG-1, OPM-2 and patient-derived cells). In
view of the potential implications for pre-clinical testing of anti-myeloma agents, we also inves-
tigated whether administration of two bone-modulating agents currently used in the clinic to
treat MM (a bisphosphonate, zoledronic acid, and a proteasome inhibitor, carfilzomib) would
prevent MBD in 2 of these models.
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Materials and Methods
Ethics statement
All procedures involving animals were approved by the Home Office (PPL 40/3462) and the
University of Sheffield’s Animal Ethics Committee. Patient cells were acquired with appropri-
ate ethical permission (REC reference: 05/Q2305/96). All participants provided written consent
to participate in this study. Original consent forms are stored in a secure location and patient
demographics and disease features entered into an encrypted database governed by the Re-
search and Development Service Sheffield Teaching Hospitals, NHS Foundation Trust UK.
This consent procedure was approved by the South Sheffield Research Ethics Committee in
August 2005 and subsequently ratified by the NHS Health Research Authority, National Re-
search Ethics Committee Yorkshire and the Humber—Sheffield in November 2012.
Myeloma cell lines and patient-derived cells
JJN3 cells (derived from the BM of a 57-year-old woman with plasma cell leukaemia at diagno-
sis) and OPM-2 cells (derived from the peripheral blood of a 56-year-old woman with MM in
the terminal leukaemia phase) were purchased from DSMZ (Germany). U266 cells (derived
from the peripheral blood of a 53-year-old man with MM) were purchased from LGC Stan-
dards (UK) and XG-1 cells (an IL-6 dependent human myeloma cell line) were a kind gift from
John Shaugnessy, Little Rock, USA. Cell lines were genetically profiled by DSMZ and ATCC
using short tandem repeat analysis to confirm their identity. Patient-derived myeloma cells
were acquired from BM aspirates of patients, where CD138 positive (CD138+) cells were col-
lected using magnetic microbeads (MACS, Miltenyi Biotec). The patient cells used in these
studies were from a Caucasian 70-year old male with plasma cell leukaemia.
Mice
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were purchased from Charles River
laboratories (UK).
Study to compare time to onset of disease, tumour burden and bone
disease
Groups of 7–8 week old female NSG mice (n = 3–5/group) were administered by intravenous
injection via the tail vein with 100 μl phosphate buffered saline (PBS, naïve control), 1x106
JJN3, U266, XG-1, OPM-2 cells or patient-derived myeloma cells. At the first signs of morbidi-
ty in each tumour group, all animals were sacrificed with a control group.
Assessment of bone disease and tumour burden
At sacrifice, the right tibiae were dissected free of soft tissue and fixed in 10% formalin before
micro-CT analysis was used to measure the percentage of trabecular bone volume (BV/TV, %),
trabecular number (Tb. N, mm-1) and the cortical bone volume (C. BV, mm3). The number
and area of cortical bone lesions (pixels2) were assessed by taking the micro-CT datasets, re-
moving the trabecular bone and then rendering the datasets to create 3D models using Drishti
(version 1.0, ANUVizlab, Australia), followed by analysis of 3 different sides of the bone using
ImageJ (version 1.47, NIH, USA). After decalcification, wax embedding and sectioning of the
tibiae, the numbers of osteoclasts (following TRAP staining) and osteoblasts on the cortico-
endosteal surfaces were assessed using standard histomorphometric methods [18]. Tumour
burden was assessed on sections of tibiae that had been stained with haematoxylin and eosin,
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where the distinct morphology of the myeloma cells distinguishes them from normal marrow.
The proportion of BM occupied by the myeloma cells was assessed using OsteoMeasure Ad-
vanced Bone Histomorphometry Video System (Osteometrics, Inc. Decatur, GA, USA) and ex-
pressed as a percentage of the whole bone section area.
A therapeutic study using JJN3-bearing mice treated with zoledronic
acid once tumour was established
Female NSG mice (7–8 weeks old) were split into 3 groups (n = 5/group). Group 1 was a non-
tumour bearing control group (Naïve). Group 2 was injected via the tail vein with 1x106 JJN3
cells and treated 13 and 15 days later, once tumour was established, with PBS subcutaneously
(JJN3). Group 3 was injected via the tail vein with 1x106 JJN3 cells and treated 13 and 15 days
later, once tumour was established, with zoledronic acid (Proctor & Gamble, 125 μg/kg subcu-
taneously twice a week) (JJN3-Zol). At the first signs of morbidity (after 3 weeks) all animals
were sacrificed. Bone disease and tumour burden were assessed as described above.
A therapeutic study using JJN3-bearing mice treated with zoledronic
acid at the time of tumour cell injection or carfilzomib once tumour was
established
Female NSG mice (7–8 weeks old) were split into 4 groups (n = 8/group). Group 1 was a non-
tumour bearing control group (Naïve). Group 2 was injected via the tail vein with 1x106 JJN3
cells and treated with vehicle (JJN3). Group 3 was injected via the tail vein with 1x106 JJN3
cells and from 7 days post tumour cell injection treated for 2 weeks with carfilzomib (Selleck-
chem, 1 mg/kg in 10% 2-hydroxypropyl-β-cyclodextrin in 0.01 M citrate buffer pH 3.5, intrave-
nously twice a week) (JJN3-Car). Group 4 was injected via the tail vein with 1x106 JJN3 cells
and treated from the time of tumour cell injection with zoledronic acid (125 μg/kg subcutane-
ously twice a week) (JJN3-Zol). At the first signs of morbidity (after 3 weeks) all animals were
sacrificed. Bone disease and tumour burden were assessed as described above.
A therapeutic study using U266-bearing mice treated with zoledronic
acid at the time of tumour cell injection or carfilzomib once tumour was
established
Female NSG mice (7–8 week old) were split into 4 groups (n = 8/group). Group 1 was a non-
tumour bearing vehicle control (Naïve). Group 2 was injected via the tail vein with 1x106 U266
cells and treated with vehicle (U266). Group 3 was injected via the tail vein with 1x106 U266
cells and from 6 weeks post tumour cell injection treated for 2 weeks with carfilzomib (Selleck-
chem, 3 mg/kg in 10% 2-hydroxypropyl-β-cyclodextrin in 0.01 M citrate buffer pH 3.5, intrave-
nously twice a week) (U266+Car). Group 4 was injected via the tail vein with 1x106 U266 cells
and treated from the time of tumour cell injection with zoledronic acid (125 μg/kg subcutane-
ously twice a week) (U266+Zol). At the first signs of morbidity all animals were sacrificed.
Bone disease and tumour burden were assessed as described above.
Statistical analysis
Data were analysed using either a Mann-Whitney test or a Kruskal-Wallis test with a Dunn’s
multiple comparisons test calculated using GraphPad Instat version 6.0b (California, USA). All
data are expressed with error bars representing standard error of mean (SEM).
Myeloma Bone Disease in NOD/SCID-GAMMAMice
PLOS ONE | DOI:10.1371/journal.pone.0119546 March 13, 2015 4 / 13
Results
We have determined the time to onset of disease, the variability in tumour burden and the ex-
tent of bone disease in NSG mice injected with 4 different myeloma cell lines and patient-de-
rived cells compared to non-tumour control mice.
Injection of JJN3, U266 or OPM-2 cells into NSGmice results in high
tumour burden and severe bone disease with low variability in tumour
burden, whereas injection of XG-1 and patient-derived cells results in
lower bone marrow infiltration and bone disease with higher variability
Injection of JJN3 cells into NSG mice resulted in an aggressive, short-term model of myeloma
with mice exhibiting signs of morbidity 3 weeks after tumour cell injection. In contrast, injec-
tion of U266, XG-1, OPM-2 or patient-derived myeloma cells resulted in less aggressive
longer-term models with mice exhibiting signs of morbidity 8 weeks after tumour cell injection.
In addition, we have injected other primary patient-derived cells (from patients with plasma
cell leukaemia or relapsed MM) into NSG mice and despite all cells infiltrating the BM and
causing MBD the variability for both was high (results not shown), similar to the patient sam-
ple shown in Fig. 1. Tumour infiltration of the BM can be seen in longitudinal sections of tibiae
from all 5 models compared to non-tumour control mice (Fig. 1Ai-vi). Tumour burden in
these bone sections varied between 98.72±0.78% and 59.45±17.50% in JJN3 or XG-1 injected
mice, respectively (Fig. 1Avii). Mice injected with JJN3, U266 and OPM-2 cells showed the
lowest variability in tumour burden, whereas the XG-1 and patient-derived cells showed the
most. A similar variation in tumour burden was also seen by FACS analysis using a human spe-
cific antibody (results not shown). Tumour infiltration of the BM was also observed in the
skull and lumbar vertebrae (results not shown).
Histological analysis also showed that tumour infiltration caused a significant increase in os-
teoclast numbers (Fig. 1Aviii) in mice injected with JJN3, U266 and OPM-2 cells, with no sig-
nificant increase observed in XG-1 or patient-derived infiltrated BM sections. Interestingly,
tumour infiltration of the BM also caused a significant decrease in osteoblast numbers on the
cortico-endosteal bone surface in all the myeloma models (Fig. 1Aix).
The extent of the bone disease in each model was assessed by micro-CT (Fig. 1Bi-vi). A sig-
nificant reduction in trabecular bone (Fig. 1Bvii) and in trabecular number (Fig. 1Bviii) was ob-
served in all myeloma treated animals except for those injected with XG-1 cells.
Cortico-endosteal measurements showed tibiae infiltrated with JJN3, U266 or OPM-2
cells had significant numbers of osteolytic lesions compared to non-tumour controls
(Fig. 1Bix & x), whereas tibiae infiltrated with XG-1 or patient-derived myeloma cells showed
no significant bone lesions compared to controls. Despite this, analysis of the cortical bone
volume only showed a significant reduction in JJN3-infiltrated tibiae compared to the non-
tumour controls (Fig. 1Bxi).
Taken together, these results show the optimal models to use to study MBD are NSG mice
injected with JJN3 cells for a short-term model, and U266 or OPM-2 cells for long-term mod-
els, given the low variability demonstrated in both tumour burden and MBD.
Zoledronic acid prevents JJN3-induced bone disease but does not
reduce tumour burden, whereas carfilzomib reduces tumour burden but
does not significantly reduce bone disease
Bisphosphonate treatment has been studied extensively in murine models of MM [19–21] and
has been implicated to have anti-tumour effects [19]. Here we studied the effect of zoledronic acid
Myeloma Bone Disease in NOD/SCID-GAMMAMice
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treatment in JJN3-bearing mice in a therapeutic approach, given once tumour was established
(Fig. 2A); and by a preventative approach, given at the time of tumour cell injection (Fig. 2B). In
addition, using a therapeutic approach we assessed the effects of the proteasome inhibitor carfilzo-
mib, which has recently been shown to have bone anabolic effects [17, 22] (Fig. 2B).
Fig. 2A shows representative longitudinal and cross-sectional micro-CT images of tibiae
from naïve NSG mice, those injected with JJN3 cells or those injected with JJN3 cells and treat-
ed with zoledronic acid from the time of tumour cell injection (Fig. 2Ai-iii). Histological analy-
sis did not show a significant reduction in tumour burden in the tibiae of mice injected with
JJN3 cells and treated with zoledronic acid compared to untreated JJN3-injected mice
(Fig. 2Aiv). However, zoledronic acid treatment did prevent JJN3-induced trabecular bone loss
Fig 1. Injection of JJN3, U266, XG-1, OPM-2 cell lines and patient-derivedmyeloma cells into NSG
mice results in varying levels of bonemarrow infiltration and osteolytic disease. A. Representative
histology images of longitudinal images and insets of tibiae from NSGmice injected with 100 μl PBS (Naïve)
(i), 1x106 JJN3 (ii), U266 (iii), XG-1 (iv), OPM-2 (v) or patient-derived myeloma cells (vi) at the end stages of
disease. Insets below show the endo-cortical (box a) and trabecular (box b) bone regions. The percentage
histological tumour area (vii), the number of osteoclasts (No. of Oc./Ec. Pm) (viii) and osteoblasts (No. of Ob./
Ec. Pm) (ix) on the cortico-endosteal surface.B. Representative longitudinal and cross-sectional micro-CT
images of tibiae from NSGmice injected with 100 μl PBS (Naïve) (i), 1x106 JJN3 (ii), U266 (iii), XG-1 (iv),
OPM-2 (v) or patient-derived myeloma cells (vi) at the end stages of disease. Micro-CT analysis of trabecular
bone volume (BV/TV, %) (vii), trabecular number (Tb. N., mm-1) (viii), the number of cortical bone lesions (ix),
the total lesion area (pixels2) (x) and the cortical bone volume (C. BV, mm3) (xi). Data are presented as mean
±SEM and significance from the non-tumour control group (Naïve) is indicated, where *p<0.05, **p<0.01,
***p<0.001 and ****p<0.0001.
doi:10.1371/journal.pone.0119546.g001
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(Fig. 2Av) and prevented cortical bone lesions (Fig. 2Avi) due to inhibition of osteoclastic bone
resorption (Fig. 2Avii). Zoledronic acid treatment had no effect on preventing JJN3-induced
reduction of osteoblasts (Fig. 2Aviii).
Fig. 2B shows representative longitudinal and cross-sectional micro-CT images of tibiae
from naïve NSG mice, those injected with JJN3 cells, those injected with JJN3 cells and then
Fig 2. Zoledronic acid prevents JJN3-induced bone disease and carfilzomib reduces tumour burden.
A. Representative longitudinal and cross-sectional micro-CT images of tibiae from NSGmice at the end
stage of disease (3 weeks post-injection of tumour cells), injected with vehicle (Naïve) (i), 1x106 JJN3 cells
(JJN3) (ii) or JJN3 cells and treated with zoledronic acid once tumour was established (JJN3+Zol) (iii). The
percentage histological tumour area (iv), micro-CT analysis of trabecular bone volume (BV/TV, %) (v) and the
number of cortical bone lesions (vi), and the number of osteoclasts (No. of Oc./Ec. Pm) (vii) and osteoblasts
(No. of Ob./Ec. Pm) (viii) on the cortico-endosteal surface.B. Representative longitudinal and cross-sectional
micro-CT images of tibiae from NSGmice at the end stage of disease, injected with vehicle (Naïve) (i), 1x106
JJN3 cells (JJN3) (ii), JJN3 cells and treated with carfilzomib once tumour was established (JJN3+Car) (iii) or
JJN3 cells and treated with zoledronic acid from the time of tumour cell injection (JJN3+Zol) (iv). The
percentage histological tumour area (v), micro-CT analysis of trabecular bone volume (BV/TV, %) (vi) and the
number of cortical bone lesions (vii), and the number of osteoclasts (No. of Oc./Ec. Pm) (viii) and osteoblasts
(No. of Ob./Ec. Pm) (ix) on the cortico-endosteal surface. Data are presented as mean±SEM and a significant
difference from the tumour control group (JJN3) is indicated, where *p<0.05, **p<0.01 and ***p<0.001.
doi:10.1371/journal.pone.0119546.g002
Myeloma Bone Disease in NOD/SCID-GAMMAMice
PLOS ONE | DOI:10.1371/journal.pone.0119546 March 13, 2015 7 / 13
treated with carfilzomib once tumour was established, or from NSG mice injected with zole-
dronic acid from the time of tumour cell injection (Fig. 2Bi-iv). Histological analysis showed a
significant reduction in tumour burden in the tibiae of mice injected with JJN3 cells and treated
with carfilzomib compared to untreated JJN3-injected mice (Fig. 2Bv) whereas, zoledronic acid
treatment showed no significant reduction in tumour burden. JJN3-induced trabecular bone
loss was not prevented in JJN3 mice treated carfilzomib, only in mice treated with zoledronic
acid (Fig. 2Bvi). Similarly, zoledronic acid treatment prevented JJN3-induced formation of cor-
tical bone lesions (Fig. 2Bvii), due to inhibition of osteoclastic bone resorption (Fig. 2Bviii),
whereas carfilzomib treatment had no significant effect on lesions or osteoclasts (Fig. 2Bvii
& viii). Neither zoledronic acid or carfilzomib treatment had any effect on preventing JJN3-
induced reduction of osteoblasts (Fig. 2Bix).
In summary NSG mice injected with JJN3 cells make an ideal short-term model to assess
the efficacy of bone modulating drugs used in the treatment of MBD.
Zoledronic acid treatment prevents U266-induced bone loss and
significantly reduces tumour burden, whereas carfilzomib treatment only
reduces tumour burden
The effects of zoledronic acid or carfilzomib were assessed in a long-term myeloma model
(NSG mice injected with U266 cells). Histological analysis of the tibiae (Fig. 3Ai-iv) showed a
significant reduction in tumour burden in mice injected with U266 cells and treated with
zoledronic acid from the time of tumour cell injection or carfilzomib once tumour was estab-
lished (Fig. 3Av).
Zoledronic acid treatment inhibited an increase in U266-induced osteoclastic bone resorp-
tion (Fig. 3Avi). However, similar to what was observed in the JJN3 NSG model, zoledronic
acid had no effect on preventing U266-induced reduction of osteoblasts (Fig. 3Avii), and inter-
estingly, the number of osteoblasts in this group were lower than the other 2 tumour groups.
Carfilzomib treatment was found to have no effect on the numbers of osteoclasts or osteoblasts
on the cortico-endosteal bone surface. Micro-CT analysis (Fig. 3Bi-iv) revealed carfilzomib
treatment partially, but not significantly, prevented U266-induced trabecular bone loss
(Fig. 3Bv) but had no effect on the formation of cortical bone lesions (Fig. 3Bvi), whereas zole-
dronic acid treatment, as predicted, prevented U266-induced trabecular bone loss and the for-
mation of cortical bone lesions, similar to its effects on JJN3-induced bone disease.
In summary NSG mice injected with U266 cells make an ideal long-term model to assess
the efficacy of bone modulating drugs used in the treatment of MBD.
Discussion
We have shown that JJN3, U266, XG-1, OPM-2 or patient-derived myeloma cells injected into
NSG mice result in various levels of BM infiltration. Mice injected with JJN3, U266 or OPM-2
cells had the highest tumour burden with the least variability, whereas XG-1 or patient-derived
cells resulted in lower tumour burden which was more variable. The time to onset of disease
was also found to vary between the NSG models. This ranged from as little as 3 weeks following
injection of the JJN3 cells, to 8 weeks with the other cell lines and patient-derived cells. This
data is similar to other reports in which myeloma cells were injected into NSG mice. Variables
in other studies included the number of cells injected, the route of administration and the
methods of analysis [8, 9, 23].
Tumour infiltration of the BM by JJN3, U266 and OPM-2 cells in NSG mice resulted in sig-
nificant trabecular bone loss and the formation of cortical bone lesions, whereas bone disease
in mice injected with XG-1 cells or patient-derived myeloma cells was more variable. In JJN3,
Myeloma Bone Disease in NOD/SCID-GAMMAMice
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U266 and OPM-2 bearing mice, an increase in cortico-endosteal osteoclast numbers was seen
to correlate with an increase in cortical bone lesions.
Our data clearly show that JJN3 cells caused an increase in osteoclastic bone resorption in
the tibiae. This is in contrast to Hjorth-Hansen et al. [24], who injected JJN3 cells into 4–6
week old female Fox Chase SCID mice and showed a decrease in TRAP positive osteoclasts.
They attributed the development of osteolytic lesions to osteoblastopenia, which consequen-
tially reduced bone formation. However, the differences seen between this study and our study
may be due to the strain of mice used or the specific anatomical region analysed. In our study,
Fig 3. Zoledronic acid treatment prevents U266-induced bone loss and significantly reduces tumour
burden, whereas carfilzomib treatment only reduces tumour burden. A. Representative longitudinal
histological images of tibiae from NSGmice at the end stage of disease, (8 weeks post-injection of tumour
cells), injected with vehicle (Naïve) (i), 1x106 U266 cells (U266) (ii), U266 cells treated with carfilzomib
(U266+Car) (iii) or zoledronic acid (U266+Zol) (iv). Insets below show the endo-cortical (box a) and trabecular
(box b) bone regions. The percentage histological tumour area (v), the number of osteoclasts (No. of Oc./Ec.
Pm) (vi) and osteoblasts (No. of Ob./Ec. Pm) (vii) on the cortico-endosteal surface. B. Representative
longitudinal and cross-sectional micro-CT images at the end stage of disease of tibiae from NSGmice
injected with vehicle (Naïve) (i), 1x106 U266 cells (U266) (ii), U266 cells treated with carfilzomib (U266+Car)
(iii) or zoledronic acid (U266+Zol) (iv). Micro-CT analysis of trabecular bone volume (BV/TV, %) (v) and the
number of cortical bone lesions (vi). Data are presented as mean±SEM and a significant difference from the
tumour control group (U266) is indicated, where *p<0.05, **p<0.01 and ***p<0.001.
doi:10.1371/journal.pone.0119546.g003
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we assessed osteoclast numbers on the cortico-endosteal surface, whereas Hjorth-Hansen et al
[24] assessed the trabecular bone region. Differences between the cortico-endosteal region and
trabecular bone compartments remain interesting but have yet to be fully elucidated.
Miyakawa et al [16] conducted histological analysis on the bone disease in sternum and
lumbar vertebrae infiltrated with U266 cells. Our results were similar with regards to the pres-
ence of osteolytic lesions and increased osteoclast numbers in tumour infiltrated bones. How-
ever, they injected 2x106 cells whereas we injected 1x106 U266 cells, which may explain why
they saw a more rapid development of disease onset at 6 weeks post-tumour cell injection,
compared to 8 weeks in our studies. In addition to histological analysis, we also assessed trabec-
ular bone loss and the development of cortical bone lesions by micro-CT, which clearly showed
the full extent of bone disease caused by the presence of U266 cells in the BM.
Fuhler et al [13] has investigated the growth of OPM-2 cells in NSG mice when adminis-
tered by intra-peritoneal injection. They found that a novel SH2 domain-containing inositol-
5’-phosphatase 1 selective chemical inhibitor (3α aminocholestane) significantly reduced the
growth of these tumour cells and enhanced the overall survival of the mice. However, no bone
disease was assessed in this study. Findings from our studies showed that OPM-2 cells, along
with U266 cells, provide robust long-term models for investigation of MBD as the tumour infil-
tration was significant and the variability between mice was low in this setting. In contrast, the
injection of XG-1 cells into NSG mice resulted in a less robust model for evaluation of MBD.
However, despite the extent of bone disease being very low and the tumour burden being more
variable than JJN3, U266 and OPM-2 cell lines, XG-1 cells did infiltrate the BM and grow. To
the best of our knowledge, the IL-6 dependent XG-1 myeloma cell line has not previously been
injected into NSG mice and this model therefore deserves further evaluation.
As well as the cell lines used in our studies, others have also assessed the use of different my-
eloma cell lines and patient-derived cells. For example, Chaidos et al. [10] demonstrated the
growth ability of patient-derived CD138+ and CD138 negative (CD138-) cell populations ad-
ministered intravenously into NSG mice, where sorted CD19-CD138+, CD19-CD138- and
CD19+ cells showed 75%, 25% and 0% BM infiltration respectively. More recently, Schueler
et al. [11] injected L363, RPMI-8226 and patient-derived myeloma cells into NSG mice. They
found BM infiltration by all cells was increased in NSG mice compared to NOD/SCID mice. In
addition, they showed that intra-tibial injection of all cells resulted in a higher tumour burden
compared to intravenous administration. Others have shown bone disease in NSG mice in-
jected with RPMI-8226 cells, this was prevented when these animals were treated after 3 weeks
with oprozomib (an orally bioavailable analogue of carfilzomib) as measured by micro-CT
analysis and levels of the bone turnover markers CTX and P1NP in serum [17]. Time to disease
onset was also assessed to be 6 weeks post-tumour cell injection.
Interestingly, osteoblast numbers were significantly decreased in all of the NSG myeloma
models we assessed, suggesting their effects on osteoblasts were independent from their effects
on osteoclasts. This is in agreement with several studies that have shown human myeloma cells
secrete several factors that suppress osteoblastic bone formation [25–29].
As predicted, JJN3- and U266-induced bone disease was prevented by zoledronic acid treat-
ment. In the JJN3 model zoledronic acid treatment was given either once tumour was estab-
lished (a treatment approach) or at the time of tumour cell injection (a preventative approach)
and both treatment protocols prevented MBD. However, neither of these treatment approaches
showed any anti-tumour effects in mice injected with JJN3 cells. These findings are similar to
those observed by Dallas et al. observed in the 5TGM1 model [20] and in contrast to what
Croucher et al. observed in the longer term 5T2MMmodel [19]. We also chose to investigate
the optimal effect of zoledronic acid in the U266 model using a preventative treatment ap-
proach. This did result in a significant reduction in tumour burden. These findings may
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provide some rational for treating patients with monoclonal gammopathy of undetermined
significance or smouldering MM i.e. before the onset of MBD with zoledronic acid in order to
prevent the onset of MBD, which constitutes symptomatic MM requiring treatment. The
mechanism of the apparent anti-tumor effect of zoledronic acid remains controversial. Yet it is
tempting to speculate that the prevention of the dysregulation of bone remodeling by zoledro-
nic acid is unconducive to tumor growth. However, the main aim of these studies were to assess
the use of bone modulating drugs in the NSG models of MM and zoledronic acid treatment ef-
fectively prevented MBD using all treatment approaches. Similar results would therefore be ex-
pected using OPM-2 cells, demonstrating that these NSG models are ideal for evaluating bone
therapeutic agents. In contrast, NSG mice injected with XG-1 cells or patient-derived myeloma
cells may not be as useful due to the low levels of bone disease. Indeed we have injected several
primary patient-derived cells into NSG mice and found high variability in tumour burden and
bone disease. However, this may not be the case for all patient-derived cells given the heteroge-
neous nature of the human disease. Others have shown, when patient-derived myeloma cells
are administered by intra-tibial injection, greater BM engraftment and reduced tumour varia-
tion is achieved [11].
In addition to hypothesising JJN3 and U266-induced MBD would be prevented by zoledro-
nic acid treatment, we investigated the effect of carfilzomib, which has previously been shown
to have bone anabolic properties [17, 22]. Despite this, carfilzomib treatment in both the JJN3
and the U266 models only reduced tumour burden and did not significantly prevent myeloma-
induced trabecular bone loss or the development of cortical bone lesions. Although in the
U266 model carfilzomib treatment partially prevented trabecular bone loss but this was not sig-
nificant. However, Hurchla et al [17], did show oprozomib prevented RPMI-8266-induced tra-
becular bone loss in NSG mice. Therefore, increasing the dose or duration of carfilzomib may
lead to beneficial effects on MBD.
In conclusion, these studies demonstrate that the inoculation of JJN3 cells into NSG mice
provides a robust and stable model over a short period of time, with an aggressive disease de-
velopment as demonstrated by high tumour burden and substantial osteolytic bone disease.
The intravenous administration of U266 or OPM-2 cells into NSG mice provide longer-term
models, which also feature consistent tumour burden and osteolytic bone disease. It is tempting
to propose that the shorter-term model provides a facsimile of aggressive, refractory disease, as
typically seen late in the disease course e.g. at relapse. The longer-term models may reflect the
less aggressive but nevertheless relentless progression of myeloma in the earlier phases
of disease.
In summary, we believe that validation of these short-term and longer-term models provide
improved platforms for pre-clinical investigations, tailored to address specific questions relating
to the response of tumour burden and MBD to novel therapeutics at various phases in MM.
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